This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
6 Sep 2011

Novartis Drug Gains EU Approval to Treat Pancreatic Neuroendocrine Tumours

The European Commission has approved Afinitor? (everolimus) tablets for the treatment of neuroendocrine tumors of pancreatic origin in adults with progressive disease.

Novartis announced that the European Commission has approved Afinitor? (everolimus) tablets for the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumors (NET) of pancreatic origin in adults with progressive disease.

 

The approval was based on Phase III data from the largest clinical trial to date in advanced pancreatic NET.

 

Approximately 60% of pancreatic NET patients are diagnosed with advanced disease. This means that the cancer has already spread to other parts of the body, and is considered aggressive and difficult to treat. The five-year survival rate for these patients is 27%.

 

Afinitor targets mTOR, a prote

Related News